Stay updated on Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Sign up to get notified when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page

  1. Check
    5 days ago
    No Change Detected
  2. Check
    12 days ago
    Change Detected
    Summary
    The access-denied screen is replaced by the full clinical-trial record, including study details, eligibility criteria, locations, outcomes, and supporting documents.
    Difference
    100%
    Check dated 2026-11-07T12:59:54.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.2 to v3.8.0; the page continues to show a 403 Forbidden error instead of study information.
    Difference
    0.2%
    Check dated 2026-10-31T13:42:19.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    A site-wide NIH notice announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence.” It appears above the page’s 403 error message.
    Difference
    1%
    Check dated 2026-10-24T16:17:50.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-17T16:10:04.000Z thumbnail image
  6. Check
    40 days ago
    Change Detected
    Summary
    The footer identifies the site as revision v3.7.1 instead of v3.7.0. The study record continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-10T15:59:56.000Z thumbnail image
  7. Check
    54 days ago
    Change Detected
    Summary
    A 403 Forbidden error now displays on the study details page, replacing the content that previously showed trial information. This prevents users from viewing enrollment details, eligibility criteria, and contact information.
    Difference
    0.5%
    Check dated 2026-09-26T17:04:33.000Z thumbnail image

Stay in the know with updates to Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Placebo in Radioiodine-Refractory Thyroid Cancer Clinical Trial page.